← Eichor
Study identifier: NCT05807139 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Spironolactone in Alcohol Use Disorder (SAUD)

Condition: Alcohol Use Disorder  ·  Sponsor: National Institute on Drug Abuse (NIDA)

PhasePhase 1
Planned participants20
Who can joinAll sexes, 21 Years to 99 Years
Healthy volunteersNo

About this study

Background: Alcohol use disorder (AUD) affects about 29.5 million people in the United States. Only 3 medicines have been approved by Food and Drug Administration to treat AUD. Researchers want to find better treatments for AUD. Animal studies found that a medicine called spironolactone, may decrease the amount of alcohol the animals drank. Spironolactone is approved to treat high blood pressure, or heart failure in people. It is not approved to treat AUD. Objective: To test a medicine (spironolactone) in people who sometimes drink excessive alcohol in order to understand how the body breaks down spironolactone and if there are any side effects in people who drink alcohol while taking this medicine. Eligibility: People aged 21 and older with AUD. Design: Participants will have 4 separate 7-day stays at a clinic in Baltimore over 2 months. Spironolactone is a capsule you swallow. Participants will take a capsule twice a day for 5 days during each clinic stay. During 1 of their 4 stays, they will take a placebo instead of the medicine. The placebo capsule looks just like the spironolactone capsule but contains no medicine. Participants will not know when they are taking the medicine or the placebo. Participants will not drink alcohol until day 6 of each clinic stay. Then they will be asked to drink alcohol in a bar-like area in the clinic. Their breath and blood alcohol levels and their well-being will be measured. Participants will undergo other tests in the clinic: …

This description comes directly from the study's public registry record.

Talk to the study team

Masoumeh Dejman  ·  (240) 987-8983  ·  masoumeh.dejman@nih.gov

Lorenzo Leggio, M.D.  ·  (667) 312-5188  ·  lorenzo.leggio@nih.gov

Always discuss trial participation with your own doctor first.

Locations (1)

National Institute on Drug AbuseBaltimore, Maryland, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05807139